Provides rapid diagnostic solutions to improve patient outcomes and reduce healthcare costs, particularly for serious infections.
Accelerate Diagnostics, Inc., headquartered in Tucson, Arizona, specializes in in vitro diagnostics, offering advanced solutions for the rapid and accurate diagnosis of severe infections across the United States, Europe, and the Middle East. At the forefront of its offerings is the Accelerate Pheno system, an innovative diagnostic platform designed for the identification and antibiotic susceptibility testing of pathogens associated with serious healthcare-associated infections. This includes a wide spectrum of gram-positive and gram-negative organisms.
Central to the Accelerate Pheno system is the Accelerate PhenoTest kit, which provides rapid identification and antibiotic susceptibility testing results. This technology is crucial for patients suspected of bacteremia or fungemia, conditions characterized by high morbidity and mortality risks, enabling healthcare providers to make informed treatment decisions swiftly and effectively.
Founded in 1982 as Accelr8 Technology Corporation, the company rebranded as Accelerate Diagnostics, Inc. in December 2012 to better reflect its focus on advancing diagnostic capabilities. Accelerate Diagnostics continues to innovate in the field of in vitro diagnostics, committed to improving patient outcomes by providing cutting-edge diagnostic tools that enhance the speed and accuracy of infectious disease diagnosis and treatment.